Morgan Eileen, Soerjomataram Isabelle, Rumgay Harriet, Coleman Helen G, Thrift Aaron P, Vignat Jérôme, Laversanne Mathieu, Ferlay Jacques, Arnold Melina
Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France.
Cancer Surveillance Branch, International Agency for Research on Cancer, Lyon, France.
Gastroenterology. 2022 Sep;163(3):649-658.e2. doi: 10.1053/j.gastro.2022.05.054. Epub 2022 Jun 4.
BACKGROUND & AIMS: The aim of this study was to provide an overview of the burden of esophageal cancer in 185 countries in 2020 and projections for the year 2040. METHODS: Estimates of esophageal cancer cases and deaths were extracted from the GLOBOCAN database for 2020. Age-standardized incidence and mortality rates were calculated overall, by sex, histologic subtype (adenocarcinoma [AC] and squamous cell carcinoma [SCC]), country, and level of human development for 185 countries. The predicted burden of incidence and mortality in 2040 was calculated based on global demographic projections. RESULTS: Globally, there were an estimated 604,100 new cases of, and 544,100 deaths from, esophageal cancer in 2020, corresponding to age-standardized incidence and mortality rates of 6.3 and 5.6 per 100,000, respectively. Most cases were SCCs (85% [512,500 cases]) and 14% (85,700 cases) were ACs. Incidence and mortality rates were 2- to 3-fold higher in male (9.3 and 8.2, respectively) compared with female (3.6 and 3.2, respectively) individuals. Global variations in incidence and mortality were observed across countries and world regions; the highest rates occurred in Eastern Asia and Southern and Eastern Africa and the lowest occurred in Western Africa and Central America regions. If rates remain stable, 957,000 new cases (141,300 AC cases and 806,000 SCC cases) and 880,000 deaths from esophageal cancer are expected in 2040. CONCLUSIONS: These updated estimates of the global burden of esophageal cancer represent an important baseline for setting priorities in policy making and developing and accelerating cancer control initiatives to reduce the current and projected burden. Although primary prevention remains key, screening and early detection represent important components of esophageal cancer control in high-risk populations.
背景与目的:本研究旨在概述2020年185个国家食管癌的疾病负担以及对2040年的预测。 方法:从全球癌症负担(GLOBOCAN)数据库中提取2020年食管癌病例和死亡的估计数据。计算了185个国家总体、按性别、组织学亚型(腺癌[AC]和鳞状细胞癌[SCC])、国家以及人类发展水平划分的年龄标准化发病率和死亡率。基于全球人口预测计算了2040年发病率和死亡率的预测负担。 结果:2020年全球估计有604,100例食管癌新发病例和544,100例死亡病例,年龄标准化发病率和死亡率分别为每10万人6.3例和5.6例。大多数病例为鳞状细胞癌(85%[512,500例]),腺癌为14%(85,700例)。男性的发病率和死亡率(分别为9.3和8.2)是女性(分别为3.6和3.2)的2至3倍。在各个国家和世界区域观察到发病率和死亡率的全球差异;最高发病率和死亡率出现在东亚以及南部和东部非洲,最低出现在西非和中美洲地区。如果发病率保持稳定,预计2040年将有957,000例食管癌新发病例(141,300例腺癌病例和806,000例鳞状细胞癌病例)以及880,000例死亡病例。 结论:这些更新后的全球食管癌疾病负担估计值是制定政策优先事项以及制定和加速癌症控制举措以减轻当前和预计负担的重要基线。尽管一级预防仍然是关键,但筛查和早期检测是高危人群食管癌控制的重要组成部分。
J Surg Oncol. 2017-4
Thorac Cancer. 2023-4
J Epidemiol Glob Health. 2024-3
Signal Transduct Target Ther. 2025-9-1